share_log

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Adverum生物技術公司宣佈,在露娜治療濕性老年性黃斑變性的第二階段試驗中,第一個受試者服用了IxO-VEC
Benzinga Real-time News ·  2022/09/14 08:08

Adverum Biotechnologies Announces First Subject Dosed With Ixo-vec In Phase 2 LUNA Trial For Treatment Of Wet Age-Related Macular Degeneration

Adverum生物技術公司宣佈,在露娜治療濕性老年性黃斑變性的第二階段試驗中,第一個受試者服用了IxO-VEC

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論